title: How addition of capecitabine might be more beneficial in the neoadjuvant treatment of breast cancer.
authors.forename: E
authors.initials: E
authors.lastname: Ararat
authors.forename: I
authors.initials: I
authors.lastname: Sahin
authors.forename: K
authors.initials: K
authors.lastname: Altundag
mesh_terms: D018943:Anthracyclines / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D020360:Neoadjuvant Therapy; D016896:Treatment Outcome
chemical_list: D018943:Anthracyclines; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil